Disease relevance of ioxaglic acid

• There was significantly less thrombophlebitis with Hexabrix than with Conray and the authors conclude that Hexabrix is safer for phlebography [1].
• A slightly higher incidence of minor side effects was noted in the Hexabrix group, mostly nausea and vomiting and urinary retention [2].
• Nausea was reported in four patients after injection of Hexabrix, and a metallic taste was significantly more frequent (p less than 0.01) with this contrast medium [3].
• Contrast media-induced ventricular fibrillation. A comparison of Hypaque-76, Hexabrix, and Omnipaque [4].
• Anaphylaxis following "Hexabrix" during routine coronary angiography [5].

High impact information on ioxaglic acid

• Conversely, an ionic HOCM (Urografin) caused only 25% degranulation, whereas an ionic LOCM (Hexabrix) caused no platelet activation and, furthermore, it inhibited the effects of thrombin on platelets [6].
• RESULTS: Hexabrix (0.1 to 0.3 mol/L), Telebrix (0.1 to 0.5 mol/L), Optiray (0.2 to 0.5 mol/L), and the corresponding pure substances concentration-dependently induced HR from basophils [7].
• In 15 patients with coronary artery disease, the mean left ventricular end-diastolic pressure increased by 4 mmHg after hexabrix compared with 10 mmHg after urografin (P less than 0.01); it returned to normal more quickly after hexabrix [8].
• The effects of an ionic contrast agent, meglumine iothalamate (Conray-60), and two newer low-osmolality radiographic contrast media, sodium meglumine ioxaglate (Hexabrix) and iopamidol (B-15,000), on platelet aggregation and secretion responses were studied [9].
• The procedure was performed with Hexabrix (sodium methylglucamine ioxaglate), Mikaelson catheters, and Gelfoam particles [10].

Chemical compound and disease context of ioxaglic acid

• The incidence of the combined primary endpoint of failed catheter laboratory outcome/requirement for bailout stenting/requirement for abciximab/myocardial infarction/death before hospital discharge was higher in the Visipaque group compared to the Hexabrix group (17.9% vs. 14.8%), although this did not reach statistical significance (P = 0.29) [11].
• Death, related to abrupt occlusion of a severe left main stenosis occurred in one patient who received Hexabrix, and acute pulmonary edema occurred in one patient who received Isovue [12].
• Thus, ischemia and reperfusion significantly dampened the coronary hemodynamic and vascular response to R76, HB, and 0.9% NaCl but not to OM [13].

Biological context of ioxaglic acid

• There were fewer perturbations of the ECG, less alteration in the diastolic blood pressure, and no serious adverse reactions noted in the Hexabrix group [14].
• The decreased osmotic diuresis associated with Hexabrix necessitated delayed bladder filming for optimal evaluation [15].
• When used for IV-DSA, the lower osmolality associated with Hexabrix offers the theoretic advantages of (1) reduced osmotic load and (2) diminished alteration in central blood volume [14].
• We prospectively examined hemodynamic, electrocardiographic, and echocardiographic indices of left ventricular function in patients undergoing contrast ventriculography with a high osmolar, ionic, monomeric contrast, diatrizoate (Renografin-76) compared with a low osmolar, ionic, dimeric contrast, ioxaglate (Hexabrix) [16].
• In the second group, HR measured by a radioimmunoassay, and PEFR measured by a peak flowmeter were investigated after injection of Hexabrix (10 patients), Telebrix (10 patients), Omnipaque (10 patients) and Iopamiron (10 patients) [17].

Anatomical context of ioxaglic acid

• Preliminary evaluation of Hexabrix for temporomandibular joint arthrography [18].
• Omnipaque vs. Hexabrix in intravenous DSA of the carotid arteries: randomized double-blind crossover study [3].
• Hypaque or Hexabrix increased myoblasts viability by 8-10% [19].
• Serious damage to the tracheal epithelium due to Hexabrix was recorded [20].
• Despite the large doses of Hexabrix used (up to 89.6 g of iodine), these tests of thyroid function did not reveal any significant change from pre-angiographic levels [21].

Associations of ioxaglic acid with other chemical compounds

• In 30 patients with varicose veins, Conray was injected into one leg and Hexabrix into the other [1].
• No patient who received Omnipaque needed hospitalization, whereas one (6%) patient who received Hexabrix was hospitalized compared to three (20%) hospitalized patients who received Hypaque [22].
• One-ml doses of Hexabrix and Renografin-76 were injected in the left coronary artery and compared [23].
• There was no difference in quality of the 26 Hexabrix and 24 Renografin exams using the continuous recursive filtration system [24].
• During the first period (the control period) a renal arteriography was performed with either iodixanol (Visipaque) or ioxaglate (Hexabrix) in a randomized order [25].

Analytical, diagnostic and therapeutic context of ioxaglic acid

• High-dose clinical urography with the low-osmolality contrast agent Hexabrix: comparison with a conventional contrast agent [26].
• Hexabrix as a contrast agent for hysterosalpingography [27].
• A comparison of Hexabrix and Renografin 60 in peripheral arteriography [2].
• Clinical experience with Hexabrix in cerebral angiography [28].
• A double-blind randomized clinical study of the use of Hexabrix in pediatric angiocardiography [29].

References